Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cytotoxic T lymphocytes (CTL) are vital for anti-tumor immunity.
• Adoptive transfer of tumor-specific CTL shows potential but is limited by poor tumor infiltration.
• Developing functionally modified CTL for enhanced tumor targeting is crucial for effective cancer immunotherapy.

Purpose of the Study:

• To engineer tumor-targeting CTL by expressing a single-chain antibody fragment (scFv) against vascular endothelial growth factor receptor 2 (VEGFR2).
• To evaluate the binding, cytotoxic activity, and in vivo efficacy of these engineered CTL.

Main Methods:

• Retroviral transduction of CTL with a gene encoding an scFv specific for VEGFR2 (flk1).
• Assessment of scFv-CTL binding to VEGFR2-expressing cells.
• Evaluation of cytotoxic activity against tumor cells.
• In vivo studies involving adoptive transfer of scFv-CTL into tumor-bearing mice.

Main Results:

• Engineered scFv-CTL successfully bound to VEGFR2-expressing cells.
• scFv-CTL maintained their cytotoxic activity against tumor cells.
• Adoptive transfer of scFv-CTL led to increased CTL accumulation in tumor tissue.
• scFv-CTL treatment effectively suppressed tumor growth in mice.

Conclusions:

• Engineering CTL to express scFv targeting tumor vascular endothelial cells (VEGFR2) is a promising strategy.
• This approach enhances CTL tumor infiltration and anti-tumor efficacy.
• scFv-CTL holds significant potential for improving adoptive immunotherapy outcomes.